Print Email

About Study Groups  |  Study Groups  |  Workshops  |  Surveys  |  Resources

MASCC Mucositis Study Group

Leadership

Chair: Sharon Elad, DMD MSc (Selad@urmc.rochester.edu) - USA
Vice-Chair: Paolo Bossi, MD (Paolo.Bossi@istitutotumori.mi.it) - Italy 
Vice-Chair: Cheng Kin Fong Karis, PhD, RN (karis_cheng@nuhs.edu.sg) - Singapore

Study Group Minutes
2017 Minutes alt - Annual Meeting - Washington, D.C.

Mission and Goals

The Mucositis Study Group's major goal is to improve outcomes of patients experiencing oral and gastrointestinal mucositis associated with anticancer therapies. This study group is a combined effort of MASCC and ISOO. Our objectives are to improve the design and conduct of clinical investigations, disseminate up-to-date educational information regarding mucositis, and serve as a resource for investigators in basic science, clinical, and health services research, as well as for industrial collaborators, clinicians, and patients.

icon  Mucositis Main Guidelines Publication
            alt MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy alt  
                       This article was first published online: 25 FEB 2014 | DOI: 10.1002/cncr.28592
               Erratum- Practice Guidelines

icon  Mucositis Guidelines Summary
          alt MASCC/ISOO Guidelines Summary alt  (Updated 7, Nov, 2014)
                       Mucositis Guidelines ©2014 MASCC, Multinational Association of Supportive Care in Cancer™ •  All rights reserved worldwide.

icon  Translations  -  Translation Policy  •  For more translation information please contact Donald Gubitosa at dgubitosa@mascc.org

icon Guideline PublicationsView All Publications related to current and previous versions of the Guidelines

icon Patient Education

The MSG has created a patient-friendly version of the Clinical Practice Guidelines for the Management of Oral Mucositis. We hope it will be helpful for patients and for healthcare providers looking for resources for their patients.
Click here to download the Information Sheets.

Past Workshops

  • Mucositis Research. Adelaide, 2016 >> Read More
  • Mucositis Research. Copenhagen, 2015 >> Read More
  • Mucositis Research. Miami, 2014 >> Read More
  • Mucositis Research. Berlin, 2013 >> Read More
  • Mucositis Research. New York City, 2012 >> Read More

Study Group News

MASCC/ISOO Clinical Practice Guidelines for Management of Mucositis Included in the National Guideline Clearinghouse
The MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy are now included in the National Guideline Clearinghouse™ (NGC). The NGC is a database of evidence-based clinical practice guidelines and related documents, maintained as a public resource by the US Agency for Healthcare Research and Quality (AHRQ), Department of Health and Human Services. Inclusion in the NGC is contingent on meeting rigorous criteria, including evidence of a systematic literature review, systematically developed recommendations for optimal care in specific clinical circumstances, and an assessment of the benefits and harms of recommended care. The NGC carries the latest update of MASCC Guidelines, linked above and published by Rajesh Lalla et al in Cancer in May, 2014 (open access).

These Guidelines represent a major accomplishment of the Mucositis Study Group. The preparation included a comprehensive, systematic review of the literature related to mucositis and the development of evidence-based clinical practice guidelines. The reviews included literature on mucositis interventions, pathogenesis, and the risk of oral and gastrointestinal mucosal injury associated with targeted cancer therapies.

MASCC/ISOO Study Group Chairs Lead Study on Oral Complications of Radiotherapy

Publications

>> View All Publications related to current and previous versions of the Guidelines

Current Guideline Publications - FREE open access to the following articles:

MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy alt 
Article first published online: 25 FEB 2014 | DOI: 10.1002/cncr.28592

The MASCC/ISOO Mucositis Guidelines: dissemination and clinical impact  - Lalla RV, Ashbury FD. 

Systematic review of basic oral care for the management of oral mucositis in cancer patients  - McGuire DB, Fulton JS, Park J, Brown CG, Correa ME, Eilers J, Elad S, Gibson F, Oberle-Edwards LK, Bowen J, Lalla RV

Systematic Review of Anti-inflammatory Agents for the Management of Oral Mucositis in Cancer Patients
Nicolatou-Galitis O, Sarri T, Bowen J, Di Palma M, Kouloulias E, Niscola P, Riesenbeck D, Stokman M, Tissing W, Yeoh E, Elad S, Lalla RV 

Systematic Review of Antimicrobials, Mucosal Coating Agents, Anesthetics, and Analgesics, for the Management of Oral Mucositis in Cancer Patients  - Saunders D, Epstein JB; Elad S; Allemano J; Bossi P; van de Wetering MD; Rao NG; Potting C; Cheng KK; Freidank A; Brennan MT; Dennis K; Bowen J; Lalla R
 
Systematic review of natural agents for the management of oral mucositis in cancer patients  - Yarom N, Ariyawardana A, Hovan A, Barasch A, Jarvis V, Jensen SB, Zadik Y, Elad S, Bowen J, Lalla RV

Systematic review of miscellaneous agents for the management of oral mucositis in cancer patients  - Jensen SB, Jarvis V, Zadik Y, Barasch A, Ariyawardana A, Hovan A, Yarom N, Lalla RV, Bowen J, Elad S

Emerging Evidence on the Pathobiology of Mucositis  - Al-Dasooqi N, Sonis ST, Bowen JM, Bateman E, Blijlevens N, Gibson RJ, Logan RM, Nair RG, Stringer AM, Yazbeck R, Elad S, Lalla RV

Risk of Oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis  - Elting LS, Chang YC, Parelkar P et al

Supportive Care in Cancer, Volume 21, Issue 11, November 2013, ISSN: 0941-4355 (Print) 1433-7339 (Online)

Related Links

The National Cancer Institute provides information on Oral Mucositis for both professionals and patients, with Spanish translations of both.


Please contact the Study Group Chairs above with your questions.
MASCC Study Group Coordinator, Don Gubitosa